International Advocacy

November 20 2013
BIO welcomes the opportunity to provide the views of its members on facilitating access to genetic resources and traditional knowledge and the sharing of benefits from their use...
October 16 2013
BIO appreciates this fourth opportunity to formally respond to the Colombian Ministry of Health’s Draft Decree on Regulatory Requirements for the Registry of Medicines of Biological Origin and we refer you to our previous comments filed to the Colombian Ministry of Health on April 24th 2012, June 12th 2012 and February 21st 2013 for background about BIO and its interest in this Decree. 
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
July 8 2013
As the Mexican government looks to establish a pathway to market for biosimilar biological products, BIO offers the following important considerations to ensure patient safety, as well as continued innovation in the life sciences industry.
June 19 2013
The TTIP represents a profoundly important opportunity to advance progress in these areas. The following comments represent BIO’s initial suggestions for the formulation of negotiating objectives relevant to biotechnology.  
November 12 2013
Event brings Western and Chinese life science companies together for partnering and deal making
April 8 2013
Strong Intellectual Property Protection Is Vital For The Life Sciences Industry.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
April 5 2012
Centric Health Resources and the National Organization for Rare Disorders (NORD), Co-organizersAlnylam Pharmaceuticals, Genzyme, a Sanofi Company and Millennium: The Takeda Oncology Company, Co-sponsors